CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening ...

Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma to a seriously ill child in Belgium, saying compassionate use rules do no ...

After receiving FDA breakthrough therapy status for its lead candidate in July, gene therapy company AveXis has released promising new safety and efficacy data. AVXS-101 is being developed to ...

AveXis’ gene therapy for spinal muscular atrophy, Zolgensma receives European approval: Basel Wednesday, May 20, 2020, 09:00 Hrs [IST] AveXis, a Novartis company, announced the European Commission (EC ...

Novartis International AG / AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families . Processed and transmitted by West Corporation. The issuer is solely ...

The biotech AveXis develops cutting-edge "gene therapy" products that could be powerful and long-lasting medical treatments. Swiss drug giant Novartis bought the biotech for $9 billion last year ...

Based on those positive results, AveXis has advanced AVXS-101 into a pivotal trial in SMA type 1, and launched a Phase I trial of the gene therapy candidate in SMA type 2, both in the U.S.

AveXis has posted top-line data from a phase 1 trial of its gene therapy against spinal muscular atrophy (SMA). All 15 patients were event-free at 13.6 months of age, a significant improvement ...

More: New gene therapy treatment could hit $1M per patient because of additional costs AveXis said it has been working on clinical studies for the treatment of spinal muscular atrophy, or SMA. The ...

AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first ...

BASEL, Switzerland, May 24, 2019 /PRNewswire/ -- AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved Zolgensma(®) (onasemnogene abeparvovac-xioi ...

AveXis, a Novartis company, today announced innovative access programs for Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal ...